Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Trading 4.4% Higher

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) traded up 4.4% during mid-day trading on Friday . The company traded as high as $0.90 and last traded at $0.71, 19,472 shares changed hands during trading. A decline of 90% from the average session volume of 196,095 shares. The stock had previously closed at $0.68.

Separately, Maxim Group initiated coverage on shares of Navidea Biopharmaceuticals in a research report on Thursday. They set a “buy” rating and a $2.00 target price on the stock.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter. The company had revenue of $0.14 million for the quarter.

In related news, major shareholder John K. Jr. Scott bought 4,000,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was bought at an average price of $0.75 per share, with a total value of $3,000,000.00. Following the transaction, the insider now owns 5,113,078 shares of the company’s stock, valued at $3,834,808.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought a total of 4,011,300 shares of company stock valued at $3,018,490 in the last three months.

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu Financial LLC raised its position in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 186,972 shares of the biopharmaceutical company’s stock after purchasing an additional 90,647 shares during the period. Virtu Financial LLC owned 0.09% of Navidea Biopharmaceuticals worth $26,000 at the end of the most recent quarter.

Navidea Biopharmaceuticals Company Profile (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Read More: Tariff

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.